** Shares of Maryland-based vaccine maker Novavax NVAX.O up 1.6% at $7.44 premarket
** Company posts Q4 adj loss of 51 cents per share vs adj loss of $1.44 per share a year ago, as it ramps down spending on COVID vaccines, its only product on market
** Co signed a licensing deal worth at least $1.2 billion with French drugmaker SanofiSASY.PA in May to hand over the rights to sell its vaccines in several markets, including the U.S. and Europe
** NVAX reports quarterly sales of $88.3 million, beating analysts' avg estimate of $84.4 million - data compiled by LSEG
** Quarterly sales of COVID vaccines came in at $49.8 million, down 80.2% from a year earlier
** NVAX has risen 33% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。